TY - JOUR
T1 - Biomarker associations with insomnia and secondary sleep outcomes in persons with and without HIV in the POPPY-Sleep substudy
T2 - a cohort study
AU - Bakewell, Nicholas
AU - Sabin, Caroline A.
AU - Negi, Riya
AU - Garcia-Leon, Alejandro
AU - Winston, Alan
AU - Sachikonye, Memory
AU - Doyle, Nicki
AU - Redline, Susan
AU - Mallon, Patrick W.G.
AU - Kunisaki, Ken M.
N1 - Publisher Copyright:
© Sleep Research Society 2022. Published by Oxford University Press on behalf of the Sleep Research Society.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Study Objectives: We investigated associations between inflammatory profiles/clusters and sleep measures in people living with HIV and demographically-/lifestyle-similar HIV-negative controls in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY)-Sleep substudy. Methods: Primary outcome was insomnia (Insomnia Severity Index [ISI]>15). Secondary sleep outcomes included 7-day actigraphy (e.g. mean/standard deviation of sleep duration/efficiency), overnight oximetry (e.g. oxygen desaturation index [ODI]) and patient-reported measures (Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires). Participants were grouped using Principal Component Analysis of 31 biomarkers across several inflammatory pathways followed by cluster analysis. Between-cluster differences in baseline characteristics and sleep outcomes were assessed using Kruskal-Wallis/logistic regression/Chi-squared/Fisher's exact tests. Results: Of the 465 participants included (74% people with HIV, median [interquartile range] age 54 [50-60] years), only 18% had insomnia and secondary sleep outcomes suggested generally good sleep (e.g. ODI 3.1/hr [1.5-6.4]). Three clusters with distinct inflammatory profiles were identified: "gut/immune activation"(n = 47), "neurovascular"(n = 209), and "reference"(relatively lower inflammation; n = 209). The "neurovascular"cluster included higher proportions of people with HIV, obesity (BMI>30 kg/m2), and previous cardiovascular disease, mental health disorder, and arthritis of knee/hip relative to the other two clusters. No clinically relevant between-cluster differences were observed in proportions with insomnia (17%, 18%, 20%) before (p =. 76) or after (p =. 75) adjustment for potential confounders. Few associations were observed among actigraphy, oximetry, and PROMIS measures. Conclusions: Although associations could exist with other sleep measures or biomarker types not assessed, our findings do not support a strong association between sleep and inflammation in people with HIV.
AB - Study Objectives: We investigated associations between inflammatory profiles/clusters and sleep measures in people living with HIV and demographically-/lifestyle-similar HIV-negative controls in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY)-Sleep substudy. Methods: Primary outcome was insomnia (Insomnia Severity Index [ISI]>15). Secondary sleep outcomes included 7-day actigraphy (e.g. mean/standard deviation of sleep duration/efficiency), overnight oximetry (e.g. oxygen desaturation index [ODI]) and patient-reported measures (Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires). Participants were grouped using Principal Component Analysis of 31 biomarkers across several inflammatory pathways followed by cluster analysis. Between-cluster differences in baseline characteristics and sleep outcomes were assessed using Kruskal-Wallis/logistic regression/Chi-squared/Fisher's exact tests. Results: Of the 465 participants included (74% people with HIV, median [interquartile range] age 54 [50-60] years), only 18% had insomnia and secondary sleep outcomes suggested generally good sleep (e.g. ODI 3.1/hr [1.5-6.4]). Three clusters with distinct inflammatory profiles were identified: "gut/immune activation"(n = 47), "neurovascular"(n = 209), and "reference"(relatively lower inflammation; n = 209). The "neurovascular"cluster included higher proportions of people with HIV, obesity (BMI>30 kg/m2), and previous cardiovascular disease, mental health disorder, and arthritis of knee/hip relative to the other two clusters. No clinically relevant between-cluster differences were observed in proportions with insomnia (17%, 18%, 20%) before (p =. 76) or after (p =. 75) adjustment for potential confounders. Few associations were observed among actigraphy, oximetry, and PROMIS measures. Conclusions: Although associations could exist with other sleep measures or biomarker types not assessed, our findings do not support a strong association between sleep and inflammation in people with HIV.
KW - HIV
KW - biomarkers
KW - inflammation
KW - insomnia
KW - sleep problems
UR - http://www.scopus.com/inward/record.url?scp=85143916941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143916941&partnerID=8YFLogxK
U2 - 10.1093/sleep/zsac212
DO - 10.1093/sleep/zsac212
M3 - Article
C2 - 36104003
AN - SCOPUS:85143916941
SN - 0161-8105
VL - 45
JO - Sleep
JF - Sleep
IS - 12
M1 - zsac212
ER -
